BioXcel Therapeutics Inc

NASDAQ:BTAIUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Contact Information

Headquarters

555 Long Wharf DrNEW HAVEN, CT, United States 06511-6107

Phone

203-643-8060

Fax

302-636-5454

Executives

Lead Independent Chairman of the Board

Peter Mueller

President, Chief Executive Officer, Director

Vimal Mehta

Chief Financial Officer, Senior Vice President

Richard Steinhart

Executive Vice President, Chief Scientific Officer

Frank Yocca

Executive Vice President, Chief of Product Development and Medical Officer

Vincent O'Neill